(294 days)
Not Found
No
The description focuses on the physical mechanism of HIFU energy delivery and thermal effects, with no mention of AI or ML for image analysis, treatment planning, or any other function.
No.
The device's stated intended use is to "achieve a desired aesthetic effect" through "non-invasive waist circumference reduction," which falls under cosmetic purposes rather than treating or diagnosing a disease or condition.
No
The device is described as delivering High Intensity Focused Ultrasound (HIFU) energy to disrupt subcutaneous adipose tissue for non-invasive waist circumference reduction, which is a therapeutic aesthetic effect, not a diagnostic one. While it is recommended to use an ultrasound imaging system before treatment to visualize the area, the device itself does not perform diagnostic imaging or analysis.
No
The device description explicitly lists hardware components such as handpieces, a control unit, a Touch LCD monitor, and a power supply unit. It also describes the physical mechanism of action involving HIFU energy delivery and thermal effects on tissue.
Based on the provided information, the SCIZER device is not an In Vitro Diagnostic (IVD).
Here's why:
- Intended Use: The intended use is to "disrupt subcutaneous adipose tissue (SAT) to provide a non-invasive approach to achieve a desired aesthetic effect" and is specifically indicated for "non-invasive waist circumference reduction." This is a therapeutic/aesthetic purpose, not a diagnostic one.
- Mechanism of Action: The device uses High Intensity Focused Ultrasound (HIFU) to cause thermal coagulation and destruction of adipose tissue. This is a physical intervention on the body, not a test performed on a sample taken from the body.
- Device Description: The description details a system that delivers energy to the body, not a system that analyzes biological samples.
- Lack of IVD Characteristics: There is no mention of analyzing blood, urine, tissue samples, or any other biological material in vitro (outside the body) to diagnose a condition, monitor a disease, or screen for a health issue.
The use of an ultrasound imaging system is mentioned, but this is for visualizing the target area before treatment, not for analyzing a sample in vitro.
Therefore, the SCIZER device is a therapeutic/aesthetic device, not an IVD.
N/A
Intended Use / Indications for Use
The SCIZER delivers high intensity focused ultrasound (HIFU) energy that can disrupt subcutaneous adipose tissue(SAT) to provide a non-invasive approach to achieve a desired aesthetic effect.
The SCIZER is specifically indicated for non-invasive waist circumference reduction.
Product codes (comma separated list FDA assigned to the subject device)
OHV
Device Description
The Subject Device consists of 2 handpieces, a control unit, a Touch LCD monitor, power supply unit for irradiation and for setting parameters after the main power and key switch is turned on.
HIFU energy is irradiated based on a linear scanning method through the handpiece depending on irradiation energy that is set in advance by the user. The Cartridge D13 used with the Subject Device focuses the HIFU energy from the transducer onto the fat layer at a depth of 13mm from the surface of the skin. The Cartridge can treat a region of tissue up to 46mm long and 46mm wide. The Cartridge can apply a maximum of 24 lines at a time. As a result, tissue temperature rises over 56°C and thermal coagulation occurs. Using thermal effects generated by the HIFU transducer, cellular disruption of the subcutaneous adipose tissue occurs. This thermal coagulation results in the contraction of the collagen and subsequently results in the destruction of the adipose tissue. The destroyed adipose tissue is cleared via an inflammatory response.
Immediately before the procedure, purified water was applied to the treatment area to promote the desired energy transmission of the ultrasound transducer. To minimize the pain from the thermal HIFU procedure, the cooling level was used through the GUI. It is recommended to use an ultrasound imaging system to visualize the sub-dermal regions of interest before treatment. It allows the physician to compile a precise view of the target treatment area.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
ultrasound imaging system
Anatomical Site
subcutaneous adipose tissue (SAT), waist, abdomen
Indicated Patient Age Range
18 and 65 years
Intended User / Care Setting
Prescription Use
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Electrical safety and Electromagnetic compatibility (EMC)
Electrical safety, and EMC was evaluated the Subject Device and complies with the following standards:
- IEC 60601-1:2005, AMD:2012, Edition 3.1
- IEC 60601-1-2 Edition 4.0 2014-02
Performance testing
Acoustic power testing, Beam Profile testing, Thermal Evaluation testing, and Focal length were performed according to Design Requirement specification, Verification, and Validation plans. The device complies with the following standards:
- IEC 60601-2-62 Edition 1.0 2013-07
- IEC 62555 Edition 1.0 2013-11
All test results were satisfactory with no deviations from the applicable standards or protocols.
Biocompatibility testing
Biocompatibility testing in accordance with ISO 10993 for skin irritation, sensitization, and cytotoxicity testing supported the biocompatibility of the patient-contacting components of the device.
- ISO 10993-5 Third Edition 2009-06-01
- ISO 10993-10 Fourth edition 2021-11
- ISO 10993-23 First edition 2021-01
Software Verification and Validation Testing:
Software Verification and Validation testing were conducted and documented as recommended by FDA's Guidance for Industry and FDA Staff, "Guidance for the Content of Premarket Submissions for Software Contained in Medical Devices." The software for this device is considered a 'Moderate' level of concern.
Animal Study
Animal Testing was conducted for evaluating the effectiveness of the Subject Device in comparison to its Predicate Device, by comparing the tissue damage, the temperature increases at the point of contact, and subcutaneous fat reduction in an animal model were performed and the test results support the substantial equivalence.
Clinical study
CLASSYS Inc. conducted a single-centered, single group, parallel clinical study with 20 study participants aged between 18 and 65 years. The study evaluated the safety and effectiveness of the Subject Device.
Efficacy outcome
The primary efficacy outcome was assessed in terms of waist circumference reduction above 2.45 cm after two sets of treatments/procedures. The treatments using the Subject Device were performed on 12 sites of the abdomen, with a cumulative energy of 150 J/cm2 and 135 J/cm2, during the 1st set and 2nd set of treatments, and were based on the umbilicus of each subject. The second procedure was executed at the 4th week after the 1st procedure and on the same sites of the participants. During the application of treatment sets, each procedure site received 3 passes within a maximum of 20 minutes. Data acquired from the subjects of this study were evaluated by FAS (Full analysis Set) and PPS (Per-Protocol Set). Additionally, Investigator Analysis Set (IAS) was added as an analysis group. The evaluation of primary efficacy outcome was done by testing the null hypothesis (D
§ 878.4590 Focused ultrasound stimulator system for aesthetic use.
(a)
Identification. A Focused Ultrasound Stimulator System for Aesthetic Use is a device using focused ultrasound to produce localized, mechanical motion within tissues and cells for the purpose of producing either localized heating for tissue coagulation or for mechanical cellular membrane disruption intended for noninvasive aesthetic use.(b)
Classification. Class II (special controls). The special control for this device is FDA's “Class II Special Controls Guidance Document: Focused Ultrasound Stimulator System for Aesthetic Use.” See § 878.1(e) for the availability of this guidance document.
0
Image /page/0/Picture/0 description: The image contains the logo of the U.S. Food and Drug Administration (FDA). On the left, there is a symbol representing the Department of Health & Human Services - USA. To the right of this symbol, there is a blue square with the letters "FDA" in white. Next to the blue square, the words "U.S. FOOD & DRUG ADMINISTRATION" are written in blue.
November 3, 2023
Classys Inc % Parul Chansoria Founder and CEO Elexes Medical Consulting, LLC 30 N Gould St Ste R Sheridan, Wyoming 82801
Re: K230100
Trade/Device Name: SCIZER (SC1-M410) Regulation Number: 21 CFR 878.4590 Regulation Name: Focused Ultrasound Stimulator System For Aesthetic Use Regulatory Class: Class II Product Code: OHV Dated: October 4, 2023 Received: October 4, 2023
Dear Parul Chansoria:
We have reviewed your section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (the Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database available at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Additional information about changes that may require a new premarket notification are provided in the FDA guidance documents entitled "Deciding When to Submit a 510(k) for a Change to an Existing Device"
1
(https://www.fda.gov/media/99812/download) and "Deciding When to Submit a 510(k) for a Software Change to an Existing Device" (https://www.fda.gov/media/99785/download).
Your device is also subject to, among other requirements, the Quality System (QS) regulation (21 CFR Part 820), which includes, but is not limited to, 21 CFR 820.30. Design controls; 21 CFR 820.90. Nonconforming product; and 21 CFR 820.100, Corrective and preventive action. Please note that regardless of whether a change requires premarket review. the OS regulation requires device manufacturers to review and approve changes to device design and production (21 CFR 820.30 and 21 CFR 820.70) and document changes and approvals in the device master record (21 CFR 820.181).
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR Part 803) for devices or postmarketing safety reporting (21 CFR Part 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR Part 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR Parts 1000-1050.
Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems.
For comprehensive regulatory information about mediation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).
Sincerely.
Mark
Digitally signed by
Mark Trumbore -S
Trumbore -S Date: 2023.11.03
13:43:38-04'00'
Mark Trumbore, Ph.D. Assistant Director DHT4A: Division of General Surgery Devices OHT4: Office of Surgical and Infection Control Devices
2
Office of Product Evaluation and Quality Center for Devices and Radiological Health
Enclosure
3
Indications for Use
510(k) Number (if known) K230100
Device Name SCIZER (SC1-M410)
Indications for Use (Describe)
The SCIZER delivers high intensity focused ultrasound (HIFU) energy that can disrupt subcutaneous adipose tissue(SAT) to provide a non-invasive approach to achieve a desired aesthetic effect.
The SCIZER is specifically indicated for non-invasive waist circumference reduction.
| Type of Use (Select one or both, as applicable) | |
|---|---|
| ☑ Prescription Use (Part 21 CFR 801 Subpart D) | |
| ☐ Over-The-Counter Use (21 CFR 801 Subpart C) |
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
4
Image /page/4/Picture/1 description: The image shows the logo for CLASSYS. The logo consists of a stylized letter C on the left, made up of three curved lines in different shades of blue. To the right of the C is the word "CLASSYS" in black, sans-serif font. Below the word "CLASSYS" is the tagline "Technology for better life" in a smaller, lighter font.
CLASSYS Inc, CLASSYS, 208, Teheran-ro, Gangnam-gu, Seoul, Republic of Korea
Contact Person:
Parul Chansoria, MS, RAC, CQA CEO & Founder, Elexes Medical Consulting Telephone: +408-475-8091 Email: parul@elexes.com
Date Prepared: November 03, 2023
5.2. Device Information
Trade name/Model No: SCIZER (SC1-M410) Classification name: Focused Ultrasound for Tissue Heat or Mechanical Cellular Disruption Regulatory class: Class II Classification panel: General and Plastic Surgery Regulation name: Focused ultrasound stimulator system for aesthetic use Product code: OHV Regulation number: 21CFR878.4590
5.3. Predicate Device Information
The Predicate Device for SCIZER (SC1-M410), hereafter referred to as the Subject Device is listed in Table 1.
| Table 1 - Predicate Device identification | ||
|---|---|---|
| Predicate Device
| Name | Manufacturer | 510K Number |
|---|---|---|
| LipoSonix® system model 2 | Solta Medical Inc. | K112626 |
5
Image /page/5/Picture/1 description: The image shows the logo for CLASSYS. The logo consists of a blue circular design on the left, followed by the word "CLASSYS" in bold, black letters. Below the word "CLASSYS" is the phrase "Technology for better life" in a smaller, lighter font. The blue circular design appears to be a stylized representation of a wave or a globe.
Device Description 5.4.
The Subject Device consists of 2 handpieces, a control unit, a Touch LCD monitor, power supply unit for irradiation and for setting parameters after the main power and key switch is turned on.
HIFU energy is irradiated based on a linear scanning method through the handpiece depending on irradiation energy that is set in advance by the user. The Cartridge D13 used with the Subject Device focuses the HIFU energy from the transducer onto the fat layer at a depth of 13mm from the surface of the skin. The Cartridge can treat a region of tissue up to 46mm long and 46mm wide. The Cartridge can apply a maximum of 24 lines at a time. As a result, tissue temperature rises over 56°C and thermal coagulation occurs. Using thermal effects generated by the HIFU transducer, cellular disruption of the subcutaneous adipose tissue occurs. This thermal coagulation results in the contraction of the collagen and subsequently results in the destruction of the adipose tissue. The destroyed adipose tissue is cleared via an inflammatory response.
Immediately before the procedure, purified water was applied to the treatment area to promote the desired energy transmission of the ultrasound transducer. To minimize the pain from the thermal HIFU procedure, the cooling level was used through the GUI. It is recommended to use an ultrasound imaging system to visualize the sub-dermal regions of interest before treatment. It allows the physician to compile a precise view of the target treatment area.
5.5. Indications for Use
The SCIZER delivers high intensity focused ultrasound (HIFU) energy that can disrupt subcutaneous adipose tissue (SAT) to provide a non-invasive approach to achieve a desired aesthetic effect.
The SCIZER is specifically indicated for non-invasive waist circumference reduction.
5.6. Comparison of Technological Characteristics with the Predicate Device
| Parameters | Subject Device
SCIZER (SC1-M410) | Predicate Device
LipoSonix® system
model 2 | Remarks |
|---------------|-------------------------------------|--------------------------------------------------|------------|
| Output Energy | HIFU Energy | HIFU energy | Equivalent |
Table 2 - Substantial equivalence comparison
6
Image /page/6/Picture/0 description: The image shows the logo for CLASSYS. The logo consists of a blue circular design on the left and the word "CLASSYS" in black on the right. Below the word "CLASSYS" is the phrase "Technology for better life" in a smaller, lighter font. The circular design is made up of three curved lines in different shades of blue.
| Frequency of Ultrasound
| output | 2 MHz | 2 MHz | Equivalent |
|---|---|---|---|
| Maximum power | |||
| delivered to the | |||
| patient | 60 J/cm2 | 60 J/cm2 | Equivalent |
| Cartridge Focal length | 13 mm | 13 mm | Equivalent |
| Treatment line | 24 line | 24 line | Equivalent |
| Treatment line/sec | 20.50 mm/sec | 20.19 mm/sec | Different |
| Space between each | |||
| treatment line | 2 mm | 2 mm | Equivalent |
| Treatment area | 46 x 46 (mm) | 46 x 46 (mm) | Equivalent |
| Treatment time | 60 minutes | 60 minutes | Equivalent |
Similarities 5.6.1.
- The intended use is equivalent for the Subject Device and . Predicate Device. Both devices belong to the same Regulatory class and both are Prescription Devices.
- . The technological characteristics such as the Energy Source, Frequency of HIFU energy, Maximum power delivered to the patient, and Cartridge Focal length are equivalent for both the Subject Device and Predicate Device.
- The treatment line is equivalent as that of the Predicate Device. ●
- The spacing between each line is equivalent for both the Subject . Device and Predicate Device.
- The treatment area is equivalent for both the Subject Device and ● Predicate Device.
- The total treatment time is equivalent for both the Subject Device and Predicate Device.
5.6.2. Differences
- Treatment line/sec is different for both the Subject Device and . Predicate Device.
7
Image /page/7/Picture/0 description: The image shows the logo for CLASSYS. The logo consists of a blue circular design on the left and the word "CLASSYS" in black on the right. Below the word "CLASSYS" is the phrase "Technology for better life" in a smaller font.
The differences between the Subject Device and the Predicate Device do not raise new questions of safety and efficacy. Testing conducted by Classys Inc. demonstrates that the Subject Device performs as intended.
5.7. Performance data
Electrical safety and Electromagnetic compatibility (EMC) 5.7.1.
Electrical safety, and EMC was evaluated the Subject Device and complies with the following standards:
- IEC 60601-1:2005, AMD:2012, Edition 3.1
- IEC 60601-1-2 Edition 4.0 2014-02
5.7.2. Performance testing
Acoustic power testing, Beam Profile testing, Thermal Evaluation testing, and Focal length were performed according to Design Requirement specification, Verification, and Validation plans. The device complies with the following standards:
- IEC 60601-2-62 Edition 1.0 2013-07 ●
- IEC 62555 Edition 1.0 2013-11 ●
All test results were satisfactory with no deviations from the applicable standards or protocols.
5.7.3. Biocompatibility testing
Biocompatibility testing in accordance with ISO 10993 for skin irritation, sensitization, and cytotoxicity testing supported the biocompatibility of the patient-contacting components of the device.
- ISO 10993-5 Third Edition 2009-06-01 ●
- ISO 10993-10 Fourth edition 2021-11 ●
- ISO 10993-23 First edition 2021-01 ●
5.7.4. Software Verification and Validation Testing:
Software Verification and Validation testing were conducted and documented as recommended by FDA's Guidance for Industry and FDA Staff, "Guidance for the Content of Premarket Submissions for Software Contained in Medical Devices." The software for this device is considered a 'Moderate' level of concern.
8
Image /page/8/Picture/1 description: The image shows the logo for CLASSYS. The logo consists of a stylized blue wave graphic on the left, followed by the word "CLASSYS" in bold, black letters. Below the word "CLASSYS" is the tagline "Technology for better life" in a smaller, lighter font.
5.8. Animal Study
Animal Testing was conducted for evaluating the effectiveness of the Subject Device in comparison to its Predicate Device, by comparing the tissue damage, the temperature increases at the point of contact, and subcutaneous fat reduction in an animal model were performed and the test results support the substantial equivalence.
5.9. Clinical study
CLASSYS Inc. conducted a single-centered, single group, parallel clinical study with 20 study participants aged between 18 and 65 years. The study evaluated the safety and effectiveness of the Subject Device.
Efficacy outcome
The primary efficacy outcome was assessed in terms of waist circumference reduction above 2.45 cm after two sets of treatments/procedures. The treatments using the Subject Device were performed on 12 sites of the abdomen. with a cumulative energy of 150 J/cm2 and 135 J/cm2, during the 1st set and 2nd set of treatments, and were based on the umbilicus of each subject. The second procedure was executed at the 4th week after the 1st procedure and on the same sites of the participants. During the application of treatment sets, each procedure site received 3 passes within a maximum of 20 minutes. Data acquired from the subjects of this study were evaluated by FAS (Full analysis Set) and PPS (Per-Protocol Set). Additionally, Investigator Analysis Set (IAS) was added as an analysis group. The evaluation of primary efficacy outcome was done by testing the null hypothesis (D